Dato-DXd Shows Promising Intracranial Activity in Advanced NSCLC Subgroups
June 3rd 2024Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.
Read More
Clinical Benefit Seen With Lenvatinib/Pembrolizumab in ccRCC, Irrespective of Biomarker Subtypes
June 3rd 2024Lenvatinib in combination with pembrolizumab yielded a greater clinical benefit rate compared with sunitinib in advanced clear cell renal cell carcinoma, regardless of patient biomarker subtype.
Read More
Subcutaneous Envafolimab Plus Lenvatinib Shows Benefit in Endometrial Cancer
June 3rd 2024Envafolimab given subcutaneously with lenvatinib shows promise in patients with advanced endometrial cancer who were not microsatellite instability-high or mismatch repair deficient after prior lines of therapy.
Read More
Enfortumab Vedotin With Pembro Improves Survival, Maintains QOL in Urothelial Cancer
June 3rd 2024A study found that enfortumab vedotin with pembrolizumab significantly improves survival and maintains quality-of-life compared with chemotherapy for locally advanced or metastatic urothelial cancer.
Read More
PolyPEPI1018 Boosts Efficacy of Atezolizumab in Metastatic MSS CRC
Published: June 3rd 2024 | Updated: June 3rd 2024PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.
Read More
Analysis Shows Low Risk of Progression With Darolutamide in nmCRPC
June 2nd 2024Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.
Read More
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
June 2nd 2024With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Read More
Data Update: 2-Year EFS Is Achieved With Neoadjuvant Enfortumab Vedotin in MIBC
June 2nd 2024Neoadjuvant enfortumab vedotin displayed promising outcomes for cisplatin-ineligible MIBC patients, achieving a 2-year EFS rate of 62.0%. Safety was affirmed with no treatment-related delays in surgery.
Read More